Nothing said here yet.
to join the conversation.
| PFEIFFER GARY MDirector | Sell | 1,203 | $292.3K | Mon, Oct 26 |
| Davis J. E.CEO and President | Sell | 10,000 | $2.4M | Tue, Sep 1 |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sell | 16,010 | $3.9M | Fri, Aug 28 |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sell | 6,237 | $1.5M | Fri, Aug 28 |
| PREVOZNIK MICHAEL ESVP & General Counsel | Sell | 430 | $105.1K | Fri, Aug 28 |
| Alan Armstrong | Buy | $8.0K | Mon, Mar 30 | Tue, Jul 21 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Julie Johnson | Buy | $8.0K | Thu, Oct 30 | Thu, Nov 6 |
| Julie Johnson | Sell | $8.0K | Thu, Oct 30 | Thu, Nov 6 |
| Carol Devine Miller | Sell | $32.5K | Mon, Mar 10 | Fri, Apr 11 |
Quest Diagnostics just posted Q3 2026 results that looked firm on paper while the stock barely flinched.
Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening.
Quest Diagnostics has delivered a strong share price run in recent years, and fresh headlines about product expansion and digital health tie-ups keep interest high.
Quest is the latest in a series of healthcare technology companies that have been hacked in recent months.
Le Qblox cluster a été intégré à plusieurs GPU NVIDIA, permettant de contrôler en temps réel le calcul hybride quantique-classique avec une latence aller-retour inférieure à 4,0 µs sur la NVIDIA RTX PRO 6000 Blackwell et inférieure à 7,2 µs sur le NVIDIA DGX…
Automation and direct-to-consumer expansion are offsetting wage inflation and Medicare reimbursement pressure, the dual challenge facing diagnostics providers.
Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and…
Revenue grew 10% as automation and AI boosted margins amid regulatory headwinds.
Moby summary of Quest Diagnostics Incorporated's Q3 2026 earnings call
Quest Diagnostics beats Q3 earnings and revenue estimates, raises its 2026 outlook on strong testing demand and margin gains, yet shares dip in pre-market trading.